{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:51:40Z","timestamp":1791579100922,"version":"4.3.4"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360029"],"award-info":[{"award-number":["82360029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.leukres.2026.108323","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:17:22Z","timestamp":1790205442000},"page":"108323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immune-mediated thrombosis in myeloproliferative neoplasms: Pathogenic pathways and clinical relevance"],"prefix":"10.1016","volume":"171","author":[{"given":"Hanlu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuege","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108323_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108323_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"Falanga","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.leukres.2026.108323_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2026.108323_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-023-00878-8","article-title":"Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm","volume":"13","author":"Tefferi","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108323_bib5","first-page":"17","article-title":"Extreme thrombocytosis in patients with overt myelofibrosis and its clinical associations","author":"Lucijanic","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.leukres.2026.108323_bib6","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib7","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108323_bib8","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib9","first-page":"23","article-title":"Thromboinflammation in myeloproliferative neoplasms (MPN)-a puzzle still to be solved","author":"Bhuria","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2026.108323_bib10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3389\/fimmu.2019.01373","article-title":"Platelets as mediators of thromboinflammation in chronic myeloproliferative neoplasms","volume":"10","author":"Marin Oyarz\u00fan","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2026.108323_bib11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/bloodadvances.2020003172","article-title":"Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature","volume":"5","author":"Alimam","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108323_bib12","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jtha.2023.01.027","article-title":"JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions","volume":"21","author":"Beckman","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2026.108323_bib13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib14","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2026.108323_bib15","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.leukres.2026.108323_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-023-00968-7","article-title":"One thousand patients with essential thrombocythemia: the Florence-CRIMM experience","volume":"14","author":"Loscocco","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108323_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-023-00972-x","article-title":"One thousand patients with essential thrombocythemia: the Mayo Clinic experience","volume":"14","author":"Gangat","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108323_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.55730\/1300-0144.6184","article-title":"Analysis of CALR-mutated essential thrombocythemia as a distinct disease entity compared with JAK2 V617F-mutated and triple-negative patients","volume":"56","author":"Aydin","year":"2026","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.leukres.2026.108323_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2229131","article-title":"MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan","volume":"28","author":"Furuya","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2026.108323_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/ejh.70113","article-title":"Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population-Based Study on Treatment Patterns, Vascular Complications and Survival","volume":"116","author":"Larsson","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108323_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41375-025-02836-8","article-title":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms","volume":"40","author":"Guy","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108323_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jtha.2023.08.028","article-title":"Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms","volume":"22","author":"Guy","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2026.108323_bib24","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1002\/ajh.26402","article-title":"Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients","volume":"97","author":"Reeves","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108323_bib25","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through \u03b21\/\u03b22 integrin activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2026.108323_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172256","article-title":"Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms","volume":"134","author":"He","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2026.108323_bib27","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib28","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2010-07-297598","article-title":"Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms","volume":"117","author":"Teofili","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000364","article-title":"Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis","volume":"4","author":"Guy","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.leukres.2026.108323_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10456-021-09783-9","article-title":"First blood: the endothelial origins of hematopoietic progenitors","volume":"24","author":"Canu","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.leukres.2026.108323_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2026.108323_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109407","article-title":"JAK2V617F-positive extracellular genomic materials drive endothelial inflammation and thrombosis in myeloproliferative neoplasms","volume":"253","author":"Toprak","year":"2025","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2026.108323_bib33","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1055\/a-2498-4849","article-title":"Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis","volume":"125","author":"De Moner","year":"2025","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.leukres.2026.108323_bib34","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00277-023-05284-5","article-title":"Contributions of bone marrow monocytes\/macrophages in myeloproliferative neoplasms with JAK2(V617F) mutation","volume":"102","author":"Fan","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108323_bib35","article-title":"Monocyte Involvement in the Pathogenesis of Myeloproliferative Neoplasms","volume":"26","author":"Li","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2026.108323_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1345402","article-title":"Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis","volume":"6","author":"Romano","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.leukres.2026.108323_bib37","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41375-024-02373-w","article-title":"Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms","volume":"38","author":"Carretta","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108323_bib38","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1158\/0008-5472.CAN-23-3553","article-title":"Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF\u03b2 Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment","volume":"84","author":"Schmidt","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2026.108323_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041906","article-title":"Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies","volume":"22","author":"Nasillo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2026.108323_bib40","first-page":"14","article-title":"Cytokine Landscapes, Immune Dysregulation, and Treatment Perspectives in Philadelphia-Negative Myeloproliferative Neoplasms: A Narrative Review","author":"Todor","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.leukres.2026.108323_bib41","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/jleuko\/qiae071","article-title":"The role of leukocytes in myeloproliferative neoplasm thromboinflammation","volume":"115","author":"Liu","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.leukres.2026.108323_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of the myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108323_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11899-022-00685-1","article-title":"Molecular Pathogenesis of Myeloproliferative Neoplasms","volume":"17","author":"Rolles","year":"2022","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2026.108323_bib44","first-page":"23","article-title":"Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications","author":"Morsia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2026.108323_bib45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108323_bib46","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.leukres.2026.108323_bib47","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/bloodadvances.2020004061","article-title":"Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events","volume":"5","author":"Schmidt","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108323_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031143","article-title":"Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms","volume":"22","author":"Ferrer-Mar\u00edn","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2026.108323_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866610","article-title":"Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression","volume":"13","author":"Carnaz Sim\u00f5es","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2026.108323_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174400","article-title":"NK Cells in Myeloproliferative Neoplasms (MPN)","volume":"13","author":"Naismith","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2026.108323_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.768592","article-title":"Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms","volume":"13","author":"Fernandes de Oliveira Costa","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2026.108323_bib52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13045-024-01562-5","article-title":"Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia","volume":"17","author":"Haage","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108323_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.leukres.2026.108323_bib54","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41375-025-02836-8","article-title":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms","volume":"40","author":"Guy","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108323_bib55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.hoc.2020.11.003","article-title":"The Microenvironment in Myeloproliferative Neoplasms","volume":"35","author":"Ramanathan","year":"2021","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"10.1016\/j.leukres.2026.108323_bib56","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1038\/s41467-022-32928-3","article-title":"Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm","volume":"13","author":"Rahman","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2026.108323_bib57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.hoc.2020.11.006","article-title":"Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms","volume":"35","author":"Schafer","year":"2021","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"10.1016\/j.leukres.2026.108323_bib58","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/ijlh.13754","article-title":"Correlation between leukocyte-platelet aggregates and thrombosis in myeloproliferative neoplasms","volume":"44","author":"\u0160efer","year":"2022","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.leukres.2026.108323_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.864735","article-title":"Endothelial Cell Phenotype, a Major Determinant of Venous Thrombo-Inflammation","volume":"9","author":"Pilard","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.leukres.2026.108323_bib60","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.2021014668","article-title":"Single-cell methods in myeloproliferative neoplasms: old questions, new technologies","volume":"141","author":"O'Sullivan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16234113","article-title":"Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations","volume":"16","author":"Carturan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2026.108323_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080854","article-title":"Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation","volume":"8","author":"Perner","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.leukres.2026.108323_bib63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/jth.14339","article-title":"Natural killer cells induce neutrophil extracellular trap formation in venous thrombosis","volume":"17","author":"Bertin","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2026.108323_bib64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12959-025-00754-4","article-title":"Causal relationship between immune cells and venous thromboembolism: a bidirectional two-sample Mendelian randomization study","volume":"23","author":"Xiao","year":"2025","journal-title":"Thromb. J."},{"key":"10.1016\/j.leukres.2026.108323_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.leukres.2026.108323_bib66","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1186\/s12885-024-12301-x","article-title":"Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study","volume":"24","author":"Xiong","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2026.108323_bib67","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41408-024-01169-6","article-title":"Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors","volume":"14","author":"Barbui","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108323_bib68","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/CCM.0b013e3181c9cbd9","article-title":"Thrombotic risk factors: basic pathophysiology","volume":"38","author":"Martinelli","year":"2010","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.leukres.2026.108323_bib69","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/bloodadvances.2024013528","article-title":"Interleukin-1\u03b2, JAK2V617F mutation and inflammation in MPNs","volume":"8","author":"Hermouet","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108323_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187712","article-title":"Fibrinogen and clot-related phenotypes determined by fibrinogen polymorphisms: Independent and IL-6-interactive associations","volume":"12","author":"Cronj\u00e9","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.leukres.2026.108323_bib71","doi-asserted-by":"crossref","first-page":"32188","DOI":"10.1038\/srep32188","article-title":"Effects of IL-1\u03b2, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity","volume":"6","author":"Bester","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2026.108323_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/biom11071036","article-title":"Fibrinogen and a Triad of Thrombosis, Inflammation, and the Renin-Angiotensin System in Premature Coronary Artery Disease in Women: A New Insight into Sex-Related Differences in the Pathogenesis of the Disease","volume":"11","author":"Kryczka","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.leukres.2026.108323_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082334","article-title":"The Role of Inflammation and Inflammasome in Myeloproliferative Disease","volume":"9","author":"Longhitano","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.leukres.2026.108323_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cells9092136","article-title":"Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants","volume":"9","author":"Masselli","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.leukres.2026.108323_bib75","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.1038\/s41598-020-63680-7","article-title":"Differential cytokine network profile in polycythemia vera and secondary polycythemia","volume":"10","author":"Cacemiro","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2026.108323_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.888763","article-title":"The Th17 Pathway in Vascular Inflammation: Culprit or Consort?","volume":"13","author":"Robert","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2026.108323_bib77","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-174835","article-title":"Proteomic Profiling and Cytokine Analysis Reveals Molecular Signatures and Inflammatory Factors Associated with Thrombosis in JAK2-V617F Positive Myeloproliferative Neoplasm (MPN) Cohorts","volume":"142","author":"Bhuria","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102561","article-title":"Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms","volume":"62","author":"De Moner","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.leukres.2026.108323_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1276353","article-title":"Chemokines, molecular drivers of thromboinflammation and immunothrombosis","volume":"14","author":"Leberzammer","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2026.108323_bib80","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/jth.14759","article-title":"Cytokine and chemokine regulation of venous thromboembolism","volume":"18","author":"Najem","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2026.108323_bib81","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6252138","article-title":"Influence of Interleukin-8 and Neutrophil Extracellular Trap (NET) Formation in the Tumor Microenvironment: Is There a Pathogenic Role?","volume":"2019","author":"Gonzalez-Aparicio","year":"2019","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.leukres.2026.108323_bib82","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108323_bib83","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms","volume":"5","author":"Hamuly\u00e1k","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108323_bib84","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2026.108323_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12657","article-title":"Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment","volume":"6","author":"Barbui","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2026.108323_bib86","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108323_bib87","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11239-015-1218-2","article-title":"Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis","volume":"40","author":"Samuelson","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.leukres.2026.108323_bib88","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241229588","article-title":"Interferons in the treatment of myeloproliferative neoplasms","volume":"15","author":"Vachhani","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.leukres.2026.108323_bib89","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib90","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib91","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108323_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202200203","article-title":"Interferon and myeloproliferative neoplasms: Evolving therapeutic approaches","volume":"45","author":"Swaroop","year":"2023","journal-title":"Bioessays"},{"key":"10.1016\/j.leukres.2026.108323_bib93","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/cam4.2741","article-title":"Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms","volume":"9","author":"Pedersen","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2026.108323_bib94","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2026.108323_bib95","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","article-title":"Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera","volume":"8","author":"S\u00f8rensen","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108323_bib96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and Treatment of Polycythemia Vera: A Review","volume":"333","author":"Tremblay","year":"2025","journal-title":"Jama"},{"key":"10.1016\/j.leukres.2026.108323_bib97","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/14656566.2024.2385729","article-title":"Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature","volume":"25","author":"Hunter","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.leukres.2026.108323_bib98","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11899-024-00744-9","article-title":"JAK Inhibitors for Myelofibrosis: Strengths and Limitations","volume":"19","author":"Thaw","year":"2024","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2026.108323_bib99","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108323_bib100","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1007\/s00277-024-05735-7","article-title":"Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice","volume":"103","author":"Chojecki","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108323_bib101","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/ejh.14124","article-title":"Ruxolitinib in patients with polycythemia vera resistant and\/or intolerant to hydroxyurea: European observational study","volume":"112","author":"Theocharides","year":"2024","journal-title":"Eur. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:20:29Z","timestamp":1791577229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":101,"alternative-id":["S0145212626001670"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108323","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-mediated thrombosis in myeloproliferative neoplasms: Pathogenic pathways and clinical relevance","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108323"}}